Can Paxlovid (nirmatrelvir/ritonavir) be initiated after 5 days of symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Paxlovid can be taken within 5 days of symptom onset for COVID-19, and taking it on day 5 is still within the recommended timeframe. According to the American College of Physicians' living, rapid practice points for the outpatient treatment of confirmed COVID-19 1, the use of nirmatrelvir–ritonavir combination therapy, which is the active ingredient in Paxlovid, is supported for symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease.

The standard regimen for Paxlovid is nirmatrelvir (300 mg) with ritonavir (100 mg) taken together twice daily for 5 days. It's essential to consult with a healthcare provider before starting Paxlovid, as it has significant drug interactions with many common medications 1. Patients should inform their doctor about all medications they're taking, including over-the-counter drugs and supplements.

Paxlovid works by inhibiting a key enzyme that the coronavirus needs to replicate, which is why early treatment is crucial - to stop viral replication before the infection becomes severe. If a patient is beyond day 5 of symptoms, they should contact their healthcare provider immediately to discuss alternative treatment options, as Paxlovid would no longer be recommended 1.

Some key points to consider when taking Paxlovid include:

  • Starting treatment within 5 days of symptom onset
  • Consulting with a healthcare provider before starting treatment
  • Informing the doctor about all medications being taken
  • Taking the standard regimen of nirmatrelvir (300 mg) with ritonavir (100 mg) twice daily for 5 days
  • Being aware of potential drug interactions and side effects.

From the FDA Drug Label

Initiate PAXLOVID treatment as soon as possible after diagnosis of COVID-19 and within 5 days of symptom onset. The FDA drug label does not explicitly state that PAXLOVID can be taken after 5 days of symptoms, but rather that treatment should be initiated within 5 days of symptom onset. Therefore, the answer to whether you can take PAXLOVID after 5 days of symptoms is no, as the treatment window is within 5 days of symptom onset 2.

From the Research

Paxlovid Treatment Timing

  • The timing of Paxlovid treatment is crucial in determining its effectiveness in treating COVID-19 symptoms 3, 4.
  • According to the study by 3, Paxlovid should be started within 5 days of symptom onset and given for 5 days' duration.
  • However, a retrospective study by 4 compared the outcomes of patients who received Paxlovid within or after five days of COVID-19 symptom onset and found that starting Paxlovid within five days reduced the length of stay and SARS-CoV-2 duration.

Efficacy of Paxlovid After 5 Days of Symptoms

  • While the recommended treatment window for Paxlovid is within 5 days of symptom onset, some studies suggest that it may still be effective when started after 5 days 4, 5.
  • A study by 4 found that severe case conversion among mild COVID-19 patients might be comparable whether starting Paxlovid within or after five days.
  • Another study by 5 compared the effectiveness of Paxlovid with other antiviral treatments and found that Paxlovid was associated with a higher proportion of virological clearance at day 7 post-treatment.

Safety and Efficacy Considerations

  • The safety and efficacy of Paxlovid have been evaluated in several studies, including those by 6, 7.
  • These studies suggest that Paxlovid is generally safe and effective in treating COVID-19 symptoms, but may have different outcomes compared to other antiviral treatments.
  • Factors such as age, comorbidities, and time from symptom onset to treatment initiation may influence the effectiveness of Paxlovid 6, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.